Interview with Paul Flapper, General Manager, Shire International Licensing BV…
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Address: Strawinskylaan six hundred fifty-nine
1 077 XX Amsterdam
,Netherlands
Tel: +31 (0) 20 364 00 74
Web: http://www.shirenederland.nl/
Shire is a global specialty biopharmaceutical company founded in 1986. Shire aims those with life-limiting illnesses helping a better life.
Shire seeks to achieve this through multiple therapeutic areas in medicine specialist to develop, produce and sell. Shire’s activities are housed in two divisions:
‘Human Genetic Therapies’ focused on genetic diseases such as Hunter syndrome, Fabry disease and hereditary angioedema.
Specialty Products’ represents the therapeutic areas of ADHD, Nephrology, Hematology and Gastroenterology.
Shire group is structured as two autonomous businesses supported by global corporate functions; business unit structure that enables small molecule entities to thrive under Shire Specialty Pharma and protein therapeutics to emerge from Shire Human Genetic Therapies
Shire Human Genetics Therapies delivers medicine in the therapeutic area lysosomal storage diseases, namely Fabry disease and Hunter syndrome.
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences…
The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was…
“Two traditions one vision” was the phrase used to describe the 2005 merger that formed Daiichi Sankyo as it is today. While referring specifically to a corporate merger, its message…
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen,…
In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual…
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Founded in 1997 Actelion is certainly the “new kid on the block” when compared to some of the much older mainstays in the pharmaceutical industry. What would you say was…
Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you doubled the size of…
See our Cookie Privacy Policy Here
